Melanoma

Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial –

2022-07-11T15:18:02+10:00Melanoma, Publications|

The primary trial aim is to determine if patient led-surveillance compared to clinician-led surveillance increases the proportion of participants who are diagnosed with a new primary or recurrent melanoma at a fast-tracked unscheduled clinic visit.

Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Caitlin Semsarian et al.

2022-03-10T15:13:49+11:00Cancer, Melanoma, Publications|

Many countries have seen a dramatic increase in the reported incidence of cutaneous melanoma in recent decades, largely driven by increased diagnoses of melanoma in situ and thin invasive melanoma. The incidence of thick and metastatic melanomas, and melanoma mortality have remained relatively stable. While [...]

Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial – Deonna Ackermann et al.

2022-02-24T16:16:03+11:00Cancer, Melanoma, Patient-led surveillance, Publications|

Patient-led surveillance is a promising new model of follow-up care after excision of localized melanoma; a larger randomized clinical trial will evaluate comparative effects on important health, psychological, and resource use outcomes.

Go to Top